Leveraging Microfluidic Technology for mRNA-LNP Manufacturing

Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.

- 

Applications ranging from vaccines to cancer immunotherapies demonstrate mRNA‘s ability to instruct cells to produce therapeutic proteins on demand..

Despite this promise, a key engineering challenge remains: safe, efficient, and reproducible delivery of fragile mRNA molecules into cells. Lipid nanoparticles (LNPs) address this challenge by encapsulating and protecting mRNA while enabling cellular uptake. However, as mRNA technologies transition from laboratory research to commercial manufacturing, conventional bulk LNP production methods are increasingly inadequate. Microfluidic technology is emerging as a powerful solution for scalable, precise, and reproducible LNP manufacturing.

Why LNPs Matter